Determining Dose Equivalence Between Oral and Transdermal Estrogen Treatment in Women With Turner Syndrome

Launched by AARHUS UNIVERSITY HOSPITAL · Aug 5, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective two forms of estrogen replacement therapy (ERT) are for women with Turner syndrome, a condition that affects development and can lead to hormone deficiencies. Specifically, the trial will compare oral estrogen (taken by mouth) with transdermal estrogen (applied to the skin) to see if they provide the same benefits. The study involves 50 women aged 18 to 50 who are already receiving estrogen treatment. Participants will take one form of treatment for two weeks, then switch to the other form for another two weeks, with a short break in between to clear the previous medication from their system.

To be eligible, women must have a diagnosis of Turner syndrome and be within the specified age range. Participants will undergo blood tests at different stages of the study to monitor their hormone levels and overall response to the treatments. This research aims to help doctors understand better how to treat hormone deficiencies in women with Turner syndrome, ensuring they receive the most effective care.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Diagnosis of TS regardless of karyotype
• • Age 18-50 years
• • Already receiving estrogen treatment
• Exclusion Criteria:
• • Active systemic chronic diseases
• • Known or suspected breast cancer
• • Known or suspected estradiol-dependent tumors (endometrial cancer or similar)
• • Untreated endometrial hyperplasia
• • Current or previous venous thromboembolism
• • Acute or previous liver disease where liver enzymes are still elevated by a factor 3 or more
• • Known hypersensitivity to the medications used
• • Pregnancy